Dario Unveils Groundbreaking GLP-1 and AI-Personalization Digital Health Findings
DarioHealth (NASDAQ: DRIO) presented four groundbreaking studies at the 85th Annual American Diabetes Association Scientific Sessions, showcasing significant achievements in GLP-1 medication management and AI-powered personalization.
A landmark study of 715 GLP-1 users demonstrated remarkable improvements, with average blood glucose dropping from eA1c of 9.0% to 6.7%. Notably, patients maintained stable outcomes for six months after discontinuing GLP-1 medication, showing no significant weight or glucose rebound.
The company's AI research achieved 89% accuracy in predicting next-month blood glucose levels using machine learning models. The studies revealed that the first four months of engagement are crucial for personalized care, with older adults (60+) showing stronger sustained outcomes.
DarioHealth (NASDAQ: DRIO) ha presentato quattro studi innovativi durante la 85ª Sessione Scientifica Annuale dell'American Diabetes Association, evidenziando importanti risultati nella gestione dei farmaci GLP-1 e nella personalizzazione basata sull'intelligenza artificiale.
Uno studio fondamentale su 715 utilizzatori di GLP-1 ha mostrato miglioramenti significativi, con la glicemia media che è passata da un eA1c del 9,0% al 6,7%. In particolare, i pazienti hanno mantenuto risultati stabili per sei mesi dopo aver interrotto la terapia con GLP-1, senza riscontri di aumento significativo di peso o glicemia.
La ricerca AI dell'azienda ha raggiunto una accuratezza dell'89% nella previsione dei livelli di glicemia del mese successivo utilizzando modelli di machine learning. Gli studi hanno evidenziato che i primi quattro mesi di coinvolgimento sono fondamentali per una cura personalizzata, con gli anziani (60+) che mostrano risultati più duraturi.
DarioHealth (NASDAQ: DRIO) presentó cuatro estudios innovadores en la 85ª Sesión Científica Anual de la Asociación Americana de Diabetes, mostrando logros significativos en la gestión de medicamentos GLP-1 y en la personalización impulsada por inteligencia artificial.
Un estudio clave con 715 usuarios de GLP-1 demostró mejoras notables, con una reducción de la glucosa promedio desde un eA1c de 9.0% a 6.7%. Es importante destacar que los pacientes mantuvieron resultados estables durante seis meses después de suspender la medicación GLP-1, sin un rebote significativo en peso o glucosa.
La investigación en IA de la empresa logró una precisión del 89% en predecir los niveles de glucosa del próximo mes utilizando modelos de aprendizaje automático. Los estudios revelaron que los primeros cuatro meses de compromiso son cruciales para la atención personalizada, siendo los adultos mayores (60+) quienes mostraron resultados más sostenidos.
DarioHealth (NASDAQ: DRIO)는 제85회 미국 당뇨병 협회 연례 학술대회에서 GLP-1 약물 관리와 AI 기반 맞춤형 치료 분야에서 중요한 성과를 보여주는 네 건의 혁신적인 연구 결과를 발표했습니다.
715명의 GLP-1 사용자를 대상으로 한 획기적인 연구에서 평균 혈당치가 eA1c 9.0%에서 6.7%로 크게 개선되었습니다. 특히, 환자들은 GLP-1 약물 중단 후 6개월 동안 안정적인 결과를 유지하며 체중이나 혈당이 크게 반등하지 않았습니다.
회사의 AI 연구는 기계 학습 모델을 사용하여 다음 달 혈당 수치를 89% 정확도로 예측하는 성과를 달성했습니다. 연구 결과는 맞춤형 치료에 있어 처음 4개월의 참여가 매우 중요하며, 60세 이상의 노인들이 더 지속적인 효과를 보인다는 점을 밝혔습니다.
DarioHealth (NASDAQ : DRIO) a présenté quatre études révolutionnaires lors de la 85e session scientifique annuelle de l'American Diabetes Association, mettant en avant des avancées majeures dans la gestion des médicaments GLP-1 et la personnalisation assistée par intelligence artificielle.
Une étude majeure portant sur 715 utilisateurs de GLP-1 a montré des améliorations remarquables, avec une baisse moyenne de la glycémie de HbA1c de 9,0 % à 6,7 %. Notamment, les patients ont conservé des résultats stables pendant six mois après l'arrêt du traitement GLP-1, sans reprise significative de poids ou de glycémie.
La recherche en IA de l'entreprise a atteint une précision de 89 % dans la prédiction des niveaux de glycémie du mois suivant grâce à des modèles d'apprentissage automatique. Les études ont révélé que les quatre premiers mois d'engagement sont cruciaux pour des soins personnalisés, les personnes âgées (60 ans et plus) affichant des résultats plus durables.
DarioHealth (NASDAQ: DRIO) präsentierte auf der 85. Jahrestagung der American Diabetes Association vier bahnbrechende Studien, die bedeutende Fortschritte im GLP-1-Medikamentenmanagement und der KI-gestützten Personalisierung zeigten.
Eine wegweisende Studie mit 715 GLP-1-Nutzern zeigte bemerkenswerte Verbesserungen, wobei der durchschnittliche Blutzucker von einem eA1c von 9,0 % auf 6,7 % sank. Bemerkenswert ist, dass die Patienten sechs Monate nach Absetzen der GLP-1-Medikation stabile Ergebnisse beibehielten, ohne signifikante Gewichtszunahme oder Blutzuckeranstieg.
Die KI-Forschung des Unternehmens erreichte eine 89%ige Genauigkeit bei der Vorhersage der Blutzuckerwerte des nächsten Monats mithilfe von Machine-Learning-Modellen. Die Studien zeigten, dass die ersten vier Monate der Teilnahme entscheidend für eine personalisierte Betreuung sind, wobei ältere Erwachsene (60+) nachhaltigere Ergebnisse erzielten.
- Blood glucose reduction from eA1c 9.0% to 6.7% in GLP-1 users
- Sustained outcomes for 6 months post-GLP-1 discontinuation with no significant rebound
- 89% accuracy in AI blood glucose prediction
- Platform demonstrates ability to maximize ROI for costly GLP-1 programs
- Strong clinical validation with 25 published studies at ADA Scientific Sessions
- None.
Insights
Dario's research shows sustained post-GLP-1 outcomes and 89% accurate AI glucose prediction, positioning them strongly in the competitive digital health market.
Dario's latest research demonstrates a significant clinical advancement in two critical healthcare areas: GLP-1 therapy sustainability and AI-powered glucose management. The landmark study of 715 GLP-1 users revealed that patients maintained stable outcomes for six months after discontinuing medication - addressing one of the biggest challenges in the GLP-1 market where rebound effects typically occur. This is evidenced by the dramatic eA1c reduction from
The AI research findings are equally compelling. Dario's machine learning model achieved
What makes these findings commercially significant is their direct application to the explosive GLP-1 market. With medications like Ozempic and Wegovy costing upwards of
The age-specific findings also reveal an often-overlooked opportunity: older adults (60+) showed stronger and more sustained outcomes with greater participation in lifestyle activities. This suggests Dario could target demographic-specific interventions, expanding their addressable market.
These studies represent Dario's 25th published research at ADA over a decade, reflecting consistent scientific investment. More importantly, the company explicitly states they're leveraging these findings in commercial discussions, indicating potential revenue acceleration in the near term.
Dario's new research shows sustained outcomes post-GLP-1 for platform users and
Key highlights from the research include a dramatic eA1c reduction from
The Company is currently leveraging these findings in ongoing implementations and commercial discussions with payers and self-insured employers seeking integrated solutions for chronic condition management, particularly around GLP-1 optimization programs.
Landmark GLP-1 Study Demonstrates Sustainable Results Beyond Medication
The first study examined 715 GLP-1 users and revealed significant clinical improvements for those engaging with Dario's platform. Most importantly, the research showed that users who discontinued GLP-1 medication maintained stable outcomes, reflecting no significant weight or glucose rebound, for at least six (6) months, addressing a critical industry challenge where patients typically experience rebound effects after stopping treatment.
Key study results included:
- Among continued GLP-1 users with elevated glucose levels, average blood glucose dropped from an eA1c of
9.0% to6.7% . - Digital lifestyle engagement activities significantly enhanced outcomes with meal and physical activity logging associated with stronger blood glucose improvements.
- Weight logging and educational content were linked to greater weight reduction.
- Members who discontinued GLP-1s experienced no significant weight or glucose rebound over six (6) months, with outcomes remaining statistically equivalent to those who continued medication.
These findings underscore the importance of integrated digital tools in supporting medication adherence, optimizing outcomes, and sustaining progress even after GLP-1 treatment ends.
"We believe that this research validates our approach to the GLP-1 market," said Omar Manejwala, M.D., Chief Medical Officer at Dario. "By demonstrating that our platform sustains outcomes beyond medication use, we believe that we are providing a solution that helps members while maximizing return on investment for health plans and employers implementing costly GLP-1 programs."
AI Research Advances Personalization in Digital Health
Three additional studies published at the ADA conference offer insights on the potential of AI and real-world data to drive more personalized, effective chronic condition management. The studies reflect early research fueling Dario's next-generation AI platform, which leverages machine learning to tailor interventions based on real-time behaviors, clinical biomarkers, and user demographics.
Key results from the studies include:
89% accuracy in predicting next-month blood glucose levels using a machine learning model informed by user behavior and activity—not just clinical data.- Machine learning revealed that the first four months of engagement and consistent self-care behaviors are key opportunities to apply AI for more personalized, adaptive diabetes care to improve outcomes.
- Age proved to be the most significant moderator of results in members with diabetes, with older adults (60+) showed stronger and more sustained outcomes with greater participation in lifestyle activities, highlighting the opportunity for age-tailored personalization.
These results showcase how Dario is using AI to turn data into dynamic care pathways, helping people achieve better outcomes through smarter, more personalized digital health experiences.
"We believe that our AI research can directly translate to commercial value," said Yifat Hershcovitz, PhD, Vice President of Clinical and Scientific Affairs at Dario. "As we implement these insights with our enterprise clients, we're delivering more personalized, effective solutions that have the potential to drive both clinical outcomes and business results."
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the Company's ability to leverage the new research findings in commercial discussions; that the Company's platform can sustain outcomes beyond medication use; that the Company's solutions will maximize return on investment for health plans and employers implementing costly GLP-1 programs; the belief that the Company's AI research will translate to commercial value; and that the Company's solutions have the potential to drive both clinical outcomes and business results. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the
DarioHealth Corporate Contact:
Mary Mooney
VP Marketing
+1-312-593-4280
DarioHealth Investor Relations Contact:
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922
Logo: https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/dario-unveils-groundbreaking-glp-1-and-ai-personalization-digital-health-findings-302489404.html
SOURCE DarioHealth Corp.
FAQ
What were the key findings of DarioHealth's (DRIO) GLP-1 study in 2025?
How accurate is DarioHealth's AI blood glucose prediction system?
What is the significance of DarioHealth's GLP-1 research for healthcare payers?
How does age affect outcomes in DarioHealth's platform users?
What role does digital engagement play in DarioHealth's GLP-1 outcomes?
